-
2022-500535-36-00
5
Moderately to severely active ulcerative colitis
-
2022-500537-84-00
5
Moderately to severely active ulcerative colitis
-
2022-501417-31-00
5
High-risk Resected Melanoma
-
2023-509421-41-03
5
Bacterial vaginosis
-
2024-513292-40-00
5
Multiple sclerosis
-
2024-515834-34-00
5
complicated acute appendicitis
-
2024-518018-22-00
5
staphylococcal endocarditis
-
2024-519655-28-00
5
Premenopausal patients with high-risk HR-positive/HER2-negative breast
-
2025-520466-22-00
5
2026-04-29
Advanced Platinum-resistant Epithelial Ovarian Cancer
-
2025-520979-13-00
5
2025-12-18
Patients with HR+ HER2- early breast cancer at intermediate risk of re
-
2023-505486-92-00
4
2024-02-09
Small bowel adenocarcinoma
-
2024-518195-31-00
6
2021-09-29
acute myocardial infarction
-
2023-507545-28-00
6
2026-03-06
Elderly patients ≥ 65 years successfully treated with percutaneous cor
-
2025-522395-92-00
5
2025-12-15
metastatic oeso-gastric adenocarcinoma
-
2024-519971-25-00
5
2025-12-03
Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer
-
2024-515875-36-00
4
2025-08-18
Advanced biliary tract cancer (BTC)
-
2024-515349-41-00
4
2025-07-29
Metastatic Breast Cancer HR+, HER2-
-
2023-506935-14-01
5
2025-06-01
Ischemic stroke
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2023-504620-26-00
4
2024-11-04
Triple negative breast cancer
-
2024-515300-39-00
4
2024-10-18
METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF G
-
2024-511070-68-01
5
2024-09-24
Ampullary adenocarcinoma
-
2024-515297-27-00
5
2024-08-14
colon carcinoma
-
2024-514107-34-00
4
2024-07-18
BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCER